ASXNotification of cessation of securities - PAR
other announcement
PAR
Paradigm Biopharmaceuticals
Pharmaceuticals, Biotechnology & Life Sciences
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Short position
short percentage0.09%
reported shorts593.5K
shares on issue626.433M
Paradigm Biopharmaceuticals (ASX:PAR) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 593,492 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.09 percentage points. Its highest recorded short interest was 4.77% in March 2022. PAR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Paradigm Biopharmaceuticals (PAR) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Update on Data Review and Convertible note redemption
other announcement
Paradigm Biopharmaceuticals appoints administrators after cancelling Phase 3 osteoarthritis trial
Paradigm Biopharmaceuticals (ASX: PAR), a Melbourne-based company developing a novel treatment osteoarthritis in knee joints, has been placed into voluntary administration after discontinuing a critical Phase 3 trial of the treatment due to an efficacy shortfall following an interim assessment. The move follows an announcement last we...
Continuation of Suspension from Quotation
other announcement
Appointment of Voluntary Administrators
other announcement
Board Initiates Voluntary Administration
other announcement
Google NewsFlagship Trial Misses, Shares Suspended: Can Paradigm (ASX:PAR) Find a Way Forward? - Kalkine Media
Flagship Trial Misses, Shares Suspended: Can Paradigm (ASX:PAR) Find a Way Forward? Kalkine Media
Continuation of Voluntary Suspension
trading_halt announcement
Notification of cessation of securities - PAR
other announcement
Agreement to Return US$2M to Obsidian
other announcement
StockheadHealth Check: Paradigm shifts trial reveal date – and investors are nervous
Paradigm Biopharma shares today moved from trading halt to suspension after the company delayed releasing its phase III knee pain ... Read More The post Health Check: Paradigm shifts trial reveal date – and investors are nervous appeared first on Stockhead.
Phase 3 Interim Result Below Continuation Threshold
other announcement
What Does Paradigm Biopharmaceuticals Limited (ASX:PAR)’s Market Securities Mean for Cannabis Stocks? - Kalkine Media
What Does Paradigm Biopharmaceuticals Limited (ASX:PAR)’s Market Securities Mean for Cannabis Stocks? Kalkine Media
Application for quotation of securities - PAR
other announcement
Dr Daniel Furtner appointed Chief Medical Officer
other announcement
Why Paradigm Biopharmaceuticals (ASX:PAR) Could Be an ASX Biotech Stock to Watch This September - Kalkine
Why Paradigm Biopharmaceuticals (ASX:PAR) Could Be an ASX Biotech Stock to Watch This September Kalkine
Application for quotation of securities - PAR
other announcement
Notification regarding unquoted securities - PAR
other announcement
Drawdown of Tranche 4 under the Convertible Note Facility
other announcement
Application for quotation of securities - PAR
other announcement
Paradigm Biopharmaceuticals (ASX:PAR): Phase 3 Progress and Funding Define the Osteoarthritis Programme - Kalkine
Paradigm Biopharmaceuticals (ASX:PAR): Phase 3 Progress and Funding Define the Osteoarthritis Programme Kalkine
Paradigm Biopharmaceuticals (ASX:PAR) Closed 10% Higher as Zilosul Nears a Pivotal Trial Review - Kalkine
Paradigm Biopharmaceuticals (ASX:PAR) Closed 10% Higher as Zilosul Nears a Pivotal Trial Review Kalkine
Paradigm Biopharmaceuticals (ASX:PAR) Advances 9%—Will Phase 3 Progress Shift Sentiment? - Kalkine
Paradigm Biopharmaceuticals (ASX:PAR) Advances 9%—Will Phase 3 Progress Shift Sentiment? Kalkine
Small Caps
June 2026 Quarterly Activities Report & Appendix 4C
other announcement
Paradigm Receives $5.75m R&D Tax Incentive Refund
other announcement
KalkineParadigm Biopharmaceuticals Raises $3 Million via Convertible Notes to Strengthen Financial Position
Paradigm Biopharmaceuticals Ltd has announced the issuance of US$3,000,000 in convertible notes under its ongoing Convertible Securities Agreement with Obsidian Global GP LLC. This capital injection is set to enhance the company’s cash reserves and provide greater financial flexibility. Investors will be keen to observe how this funding influences Paradigm's strategic projects and overall financial stability. Key Points Paradigm Biopharmaceuticals Ltd (ASX:PAR) Issued US$3,000,000 in conver...
Drawdown of Tranche 4 under the Convertible Note Facility
other announcement
Paradigm Biopharmaceuticals (ASX:PAR) Is Gaining Investor Attention — Here's Why - Kalkine
Paradigm Biopharmaceuticals (ASX:PAR) Is Gaining Investor Attention — Here's Why Kalkine
Listing of Options - Top 20 Holders and Distribution Reports
other announcement
Paradigm Biopharma (ASX:PAR) Shares Jump on Monday – Here’s Why - Kalkine
Paradigm Biopharma (ASX:PAR) Shares Jump on Monday – Here’s Why Kalkine
Why Paradigm’s Massive New Share Issue Is Drawing Attention
Highlights Paradigm Biopharmaceuticals applied for quotation of more than forty-three million new ordinary shares on the ASX. The expanded share base is expected to increase trading liquidity and market participation. The move supports the company’s ongoing capital management and pharmaceutical development activities. Paradigm Biopharmaceuticals has applied to quote more than forty-three million new shares on the ASX. The move expands tradable securities, enhances liquidity Paradigm Bio...